Proof of Concept Data for Colorista® Capsules Used with Imago BioSciences’ Bomedemstat Presented at the AAPS Pharmsci 360 Virtual Conference
Poster presentation by Lonza Pharma & Biotech
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc., (“Imago”) a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that its clinical trial material partner, Lonza Pharma & Biotech, presented data from an application of its Colorista® capsules used with Imago’s compound, bomedemstat (IMG-7289), at the American Association of Pharmaceutical Scientists (AAPS) Pharmsci 360 Virtual Meeting.
The poster presentation discussed the use of Colorista® capsules to manufacture a formulation of bomedemstat that is more stable to heat, oxygen and moisture than a tablet formulation. The presentation includes a summary of manufacturing and developmental processes that influence the stability of the formulated Colorista® capsules. These capsules also simulate the different potential colors for a commercial product – a process that can benefit companies such as Imago that at this stage in development do not have branded capsule stamps or colors.
“Study findings will expedite our decision on future capsule options and significantly reduce the risk of compatibility in late stage clinical studies,” said Amy E. Tapper, Ph.D., Senior Vice President, Non-clinical and CMC, Imago BioSciences. “As we progress our pipeline, this study allows our commercial team to evaluate multiple color options and design the most stable oral delivery system for patients.”
- Title: Case Study – Application of Colorista® Capsules for Rapid Product Development with Proof of Concept Data for a Heat, Oxygen, and Moisture Sensitive Compound
- Session/Track: Formulation and Delivery – Chemical – Formulation – Oral – Immediate Release
- Presenter: Namrata Vora, MS, Research Scientist III, Lonza Pharma & Biotech
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders targeting epigenetic enzymes. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. Imago is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago BioSciences is backed by leading strategic and venture investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Amgen Ventures, MRL Ventures Fund, HighLight Capital, Pharmaron, Greenspring Associates and Xeraya Capital. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.